07.02.2019 • NewsBASFDede WillamsSolenis

Solenis and BASF Close Paper and Water Merger

Solenis and BASF Close Paper and Water Merger (c) Solenis
Solenis and BASF Close Paper and Water Merger (c) Solenis

BASF has completed the merger of its wet-end Paper and Water Chemicals business into Solenis following all regulatory approvals. Financial terms were not disclosed.

The combined global specialty chemical company focused on paper and industrial water technologies will operate under the Solenis name, employ around 5,000 people and have pro forma sales of about $3 billion.

BASF will be the minority partner in the combined company, with the 51% majority owned collectively owned by Solenis management and funds managed by Clayton, Dubilier & Rice (CD&R).

With 5,200 employees worldwide, the new Solenis said it will have increased sales, service and production capabilities providing expanded chemical offerings and cost-effective solutions for customers in pulp, paper, oil and gas, chemical processing, mining, bio-refining, power, municipal and other industrial markets.

BASF is contributing the paper and water assets of its Performance Chemicals unit, including production sites in Bradford and Grimsby, UK; Suffolk, Virginia, USA; Altamira, Mexico; Ankleshwar, India and Kwinana, Australia, along with related assets including intellectual property. Its paper coating chemical business will not be part of the new company.

Prior to the conclusion of the transaction, the US arm of the Ludwigshafen group, BASF Corporation, planned to close two production sites in South Carolina, eliminating around 50 jobs.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read